Bibliografía
1.Antonescu CR.
Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.
Modern Pathology 2008;21:S31-S36
2.Eizaguirre B,Burgos JJ.
Tumores GIST. Revisión de la literatura.
Rev Esp Patol 2006;39:209-18
3.Fernandez JA, Parrilla P.
Tratamiento quirúrgico del GIST avanzado en la era del imatinib.
Cir Esp 2009;86:3-12
4.Fletcher CD, Berman JJ et al.
Diagnosis of Gastrointestinal Stromal Tumors: A Consensus
Approach.
Hum Pathol 2002;33:459-465
5.Hornick JL, Fletcher CH.
The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hum Pathol 2007;38:679-687
6.Joensuu H.
Risk stratification of patients diagnosed with gastrointestinal stromal tumor.
Hum Pathol 2008;39:1411-9
7.Lasota J, Miettinen M.
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Histopathology 2008;53:245-266
8.Liegl B Hornick JL et al.
Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.
Am J Surg Pathol 2009;33:437-46
9.Loughrey M, Trivett M et al.
KIT immunohistochemistry and mutation status in
gastrointestinal stromal tumours (GISTs) evaluated for
treatment with imatinib.
Histopathology 2006, 49, 52–65
10.Medeiros F, Fletcher CH et al. KIT-negative gastrointestinal stromal tumors.
Am J Surg Pathol 2004;28:889-894
11.Miettinen M, Sobin LH, Lasota J.
Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical and molecular genetic study of 1765 cases with long-term follow-up.
Am J Surg Pathol 2005;29:52-68
12.Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.
Am J Surg Pathol 2009;33:1401-8 13.Nilsson B, Kindblom LG et al.
Gastrointestinal Stromal Tumors: The Incidence,
Prevalence, Clinical Course, and Prognostication in
the Preimatinib Mesylate Era.A Population-Based Study in Western Sweden.
Cancer 2005;103:821–9
14.Miselli F,Millefani C et al.
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.
Am J Surg Pathol 2008;32:738-43
15.Peterson M, Zhe Piao, Wiedner N et al.
Strong PDGFRA positivity is seen in GIST but not in other intraabdominal mesenchimal tumors: immunohistochemical and mutational analysis.
Appl Immunohistochem Mol Morphol 2006;14:390-396
16.Poveda A, Artigas V, et cols. Grupo español de investigación en sarcomas (GEIS).
Guía de práctica clínica en los tumores estromales gastrointestinales (GIST): actualización 2008.
Cir Esp 2008;84(supl1):1-21
17.Reichardt P, Schneider U et al.
Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate.
J Clin Pathol 2004;57:215-217
18.Rossi S, Dei Tos A.
Chromosomal imbalance and cytogenetic progression in gastrointestinal stromal tumor.
Adv Ant Pathol 2007; 14:301-302
19.Rubin BP.
Gastrointestinal stromal tumors: an update.
Histopathology 2006;48:83-96
20.Sanne M. van der Zwan, M. et al.
Gastrointestinal Stromal Tumor: 5 Years Later.
Cancer 2005;104:1781–8
21.Streutker CJ, Huizinga JD. et al.
Interstitial cells of Cajal in health and disease. Part II: ICC and
gastrointestinal stromal tumours.
Histopathology 2007, 50, 190–202
22.Tornillo L, Terracciano LM.
An update on molecular genetics of gastrointestinal stromal tumors.
J Clin Pathol 2006;59:557-563
|